Nevertheless, scientific trials of type II FLT3 inhibitors commonly exclude individuals with any kind of FLT3 D835 mutation because of a prevailing assumption that FLT3 D835 substitutions uniformly confer resistance to type II inhibitors
Nevertheless, scientific trials of type II FLT3 inhibitors commonly exclude individuals with any kind of FLT3 D835 mutation because of a prevailing assumption that FLT3 D835 substitutions uniformly confer resistance to type II inhibitors. level of resistance to sorafenib1, 6. The most frequent C-75 Trans residue implicated in scientific level of resistance to FLT3 TKI … Read more